Coeptis Therapeutics - COEP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.33
  • Forecasted Upside: 789.07%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.49
▼ -0.04 (-7.58%)

This chart shows the closing price for COEP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Coeptis Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for COEP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COEP

Analyst Price Target is $4.33
▲ +789.07% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Coeptis Therapeutics in the last 3 months. The average price target is $4.33, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 789.07% upside from the last price of $0.49.

This chart shows the closing price for COEP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Coeptis Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2023LADENBURG THALM/SH SHInitiated CoverageBuy$3.00Low
4/19/2023JonestradingInitiated CoverageBuy$4.00Low
4/5/2023EF Hutton Acquisition Co. IReiterated RatingBuy$6.00Low
3/29/2023EF Hutton Acquisition Co. IReiterated RatingBuy$6.00N/A
12/12/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$6.00Low
(Data available from 2/22/2019 forward)

News Sentiment Rating

-0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/26/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/25/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/24/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/22/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Very Positive

  • No very positive mentions tracked during this time.
Coeptis Therapeutics logo
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Read More

Today's Range

Now: $0.49
Low: $0.47
High: $0.56

50 Day Range

MA: $0.64
Low: $0.33
High: $0.94

52 Week Range

Now: $0.49
Low: $0.33
High: $2.19

Volume

168,096 shs

Average Volume

161,215 shs

Market Capitalization

$16.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Coeptis Therapeutics?

The following sell-side analysts have issued stock ratings on Coeptis Therapeutics in the last year: EF Hutton Acquisition Co. I, Jonestrading, and LADENBURG THALM/SH SH.
View the latest analyst ratings for COEP.

What is the current price target for Coeptis Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Coeptis Therapeutics in the last year. Their average twelve-month price target is $4.33, suggesting a possible upside of 789.1%. EF Hutton Acquisition Co. I has the highest price target set, predicting COEP will reach $6.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $3.00 for Coeptis Therapeutics in the next year.
View the latest price targets for COEP.

What is the current consensus analyst rating for Coeptis Therapeutics?

Coeptis Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe COEP will outperform the market and that investors should add to their positions of Coeptis Therapeutics.
View the latest ratings for COEP.

What other companies compete with Coeptis Therapeutics?

How do I contact Coeptis Therapeutics' investor relations team?

Coeptis Therapeutics' physical mailing address is 801 S POINTE DRIVE SUITE TH-1, MIAMI BEACH FL, 33139. The company's listed phone number is 724-934-6467 and its investor relations email address is [email protected]. The official website for Coeptis Therapeutics is coeptispharma.com. Learn More about contacing Coeptis Therapeutics investor relations.